MA-VERACODE
11.1.2023 13:51:42 CET | Business Wire | Press release
Veracode, a leading global provider of modern application security testing solutions, today revealed data that could save organizations time and money by helping developers minimize the introduction and accumulation of security flaws in their software. The Veracode State of Software Security 2023 report found that flaw build-up over time is such that nearly 32 percent of applications are found to have flaws at the first scan and by the time they have been in production for five years, nearly 70 percent contain at least one security flaw. Veracode has been publishing its annual report since 2010, summarizing the key discoveries from its diverse customer base.
With the cost of a data breach averaging $4.35 million*, teams should prioritize remediation early in the software development life cycle to minimize risk caused by flaw accumulation. Chris Eng, Chief Research Officer at Veracode, said, “As with all our studies, we set out to provide insights that developers can put into action right away. From this year’s findings, two important considerations emerged: how to lower the chance of flaws being introduced in the first place, and how to reduce the number of those flaws that are introduced. Aside from technical access controls, secure coding practices are all the more crucial for cybersecurity in 2023 and beyond.”
No Direct Correlation Between App Growth and Flaw Introduction
After the initial scan, apps quickly enter a ‘honeymoon period’ of stability, and nearly 80 percent do not take on any new flaws at all for the first 1.5 years. After this point, however, the number of new flaws introduced begins to climb again to approximately 35 percent at the five-year mark.
The study found that developer training, use of multiple scan types, including scanning via API, and scan frequency are influential factors in reducing the probability of flaw introduction, suggesting teams should make them key components of their software security programs. For example, skipping months between scans correlates with an increased chance that flaws will be found when a scan is eventually run. Furthermore, top flaws in apps vary by testing type, highlighting the importance of using multiple scan types to ensure hard-to-identify flaws aren’t missed.
The Fragility of Open Source
With heightened focus on the Software Bill of Materials over the past year, Veracode’s research team also examined 30,000 open-source repositories publicly hosted on GitHub. Interestingly, 10 percent of repositories hadn’t had a commit—a change to the source code—for almost six years. Eng said, “Using a software composition analysis (SCA) solution that leverages multiple sources for flaws, beyond the National Vulnerability Database, will give advance warning to teams once a vulnerability is disclosed and enable them to implement safeguards more quickly, hopefully before exploitation begins. Setting organizational policies around vulnerability detection and management is also recommended, as well as considering ways to reduce third-party dependencies.”
An Ounce of Prevention is Worth a Pound of Cure: Steps to Success
Veracode’s research reveals key steps that security and development teams should take:
- Tackle technical or security debt as early and quickly as possible. The remediation curve must fall earlier and faster because an application will have accumulated flaws by the time it is two years old. Whether through increasing complexity from years of steady growth or diminishing focus on application development, this trend continues upwards, meaning there is a 90 percent chance an application will contain at least one flaw by the 10-year mark. Scanning frequently using a variety of tools helps to find and fix flaws that may have been introduced or built up over time.
- Prioritize automation and developer security training to provide understanding of which vulnerabilities are most likely to be introduced, as well as techniques to avoid introducing flaws altogether. Overall, the data shows a 27 percent chance that new flaws will be introduced in an application in any given month. Organizations that scan via API reduce this probability to 25 percent. Those that complete 10 Security Labs—a training platform offering hands-on vulnerability detection and remediation experience—also reduce the probability of flaws being introduced by 1.8 percent in any given month.
- Establish an application lifecycle management protocol that incorporates change management, resource allocation, and organizational controls. Investigate what the supportability and quality control phases look like in your organization. Initial discussions could lead to planned obsolescence for some applications and a review of the processes and quality control measures involved in continuous product engineering.
Jay Jacobs, Co-founder and Data Scientist at The Cyentia Institute, with whom Veracode produced the report, closed, “With Veracode’s State of Software Report, it’s fascinating to examine flaw accumulation and behavior by drawing upon nearly two decades of data. The breadth and depth of the data enables us to not just identify best practices, but also some of the more subtle factors that need to be addressed early in the development process to minimize risk later down the line.”
The Veracode State of Software Security 2023 study analyzed more than three quarters of a million applications across commercial software suppliers, software outsourcers, and open-source projects. The full report is available to download here.
* IBM Security and The Ponemon Institute, “Cost of a Data Breach Report 2022”, July 2022, https://www.ibm.com/downloads/cas/3R8N1DZJ
About the State of Software Security Report
The Veracode State of Software Security 2023 report analyzed data from large and small companies, commercial software suppliers, software outsourcers, and open-source projects. The report contains findings from more than three quarters of a million (759,445) applications that used all scan types, more than a million (1,262,147) dynamic analysis scans, more than seven million (7,522,989) static analysis scans, and more than 18 million (18,473,203) software composition analysis scans. All those scans produced 86 million raw static findings, 3.7 million raw dynamic findings, and 8.5 million raw software composition analysis findings.
About Veracode
Veracode is a leading AppSec partner for creating secure software, reducing the risk of security breach, and increasing security and development teams’ productivity. As a result, companies using Veracode can move their business, and the world, forward. With its combination of process automation, integrations, speed, and responsiveness, Veracode helps companies get accurate and reliable results to focus their efforts on fixing, not just finding, potential vulnerabilities. Learn more at www.veracode.com, on the Veracode blog, on LinkedIn, and on Twitter.
Copyright © 2023 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230111005141/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
